Two national trials have shown that Paxlovid helps vaccinated adults recover from COVID-19 faster but does not reduce hospitalizations or deaths, providing critical guidance for clinicians on patient selection. This matters as it clarifies the drug's efficacy in highly vaccinated populations and may influence future treatment guidelines to focus on those at highest risk.
Read the full article at Digital Journal
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.





